

# Leader du SaaS pour la pharmacovigilance en forte croissance



**MERGERSCORP**

## Leader du SaaS pour la pharmacovigilance en forte croissance

Société SaaS à croissance rapide, basée à Bangalore et disposant de bureaux aux États-Unis, au Royaume-Uni et en Europe, spécialisée dans les solutions informatiques de pharmacovigilance (PV) et d'essais cliniques pour l'industrie mondiale des sciences de la vie. L'entreprise propose une plateforme tout-en-un combinant l'accueil, le traitement des dossiers, les soumissions réglementaires et la détection des signaux, ce qui permet de réduire les coûts informatiques jusqu'à 70 % et les délais de mise en conformité de 30 %.

Fondée en 2017, la société dispose d'une équipe spécialisée dans le domaine de 65+ employés basés en Inde et soutient 100+ clients directs et plus de 160 clients finaux à travers plus de 15 pays.

### Capacités de la plate-forme de base

- Base de données PV unifiée avec AS2 Gateway
- Modules d'admission par Internet, par courrier électronique et par MICC
- Traitement des cas, récits automatiques, détection des signaux
- Support E2B R2/R3 et analyse en temps réel
- Modules intégrés CTMS, EDC, eTMF, ePRO, IWRS et eConsent

### Différenciation

- Automatismes alimentés par l'IA pour l'enregistrement, le triage et le traitement des dossiers
- Système unifié de bout en bout (par opposition aux outils fragmentés des piles existantes)
- Outils de conformité réglementaire intégrés (par exemple, soumissions, rapports)
- Trois des dix plus grandes sociétés pharmaceutiques indiennes lui font confiance.

### Empreinte stratégique

GROSS REVENUE  
\$ 3,000,000

EBITDA  
\$ 1,000,000

BUSINESS TYPE  
Logiciels et SAAS

COUNTRY  
Inde

BUSINESS ID  
L#20250961

- Forte présence en Inde, aux États-Unis, au Royaume-Uni et dans l'ensemble de l'Europe
- Intégrés dans des ORC mondiales et en expansion grâce à des partenariats (par exemple, Wipro, Persistent, Cognizant)
- Utilisé activement dans plus de 250 études cliniques

#### La vision

- 2025 : Automatisation des flux de travail de pharmacovigilance grâce à l'IA
- 2030 : Devenir l'un des 10 premiers fournisseurs mondiaux de technologies photovoltaïques, avec une part de marché de 30%.

*The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction*

*The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.*

*By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.*

*This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.*

*The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.*

*All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.*

## MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

**MERGERSCORP**

[WWW.MERGERSCORP.COM](http://WWW.MERGERSCORP.COM)